Status: Active, recruiting
Type: Prospective observational cohort
Sponsor: Radboud University Medical Center
Enrollment: 650 participants
Study Start: January 2018
Estimated Completion: December 2030
Location: Nijmegen, Netherlands
Overview
The Personalized Parkinson Project is one of the most ambitious longitudinal observational studies in Parkinson's disease (PD) conducted to date. This large-scale, single-center study at Radboud University Medical Center in the Netherlands aims to establish a comprehensive dataset that will enable precision medicine approaches for PD patients. Unlike traditional clinical trials that focus on specific interventions, this study is designed to generate deep phenotypic and genotypic data that can be leveraged to understand disease heterogeneity, predict progression, and ultimately guide personalized treatment strategies[@bloem2018].
The project represents a paradigm shift in PD research—from broad, one-size-fits-all approaches to detailed characterization of individual patients that can inform targeted therapies. By collecting extensive clinical, imaging, genetic, and biomarker data over a 10-year follow-up period, the study creates a resource that will benefit the entire PD research community and accelerate the development of disease-modifying therapies.
Background
The Challenge of Heterogeneity in Parkinson's Disease
Parkinson's disease affects approximately 10 million people worldwide, and its clinical presentation varies dramatically between individuals. This heterogeneity presents a fundamental challenge for both clinical care and therapeutic development:
Clinical Heterogeneity
- Motor symptoms: Tremor-dominant vs. postural instability/gait difficulty (PIGD) subtypes
- Non-motor symptoms: Varying combinations of cognitive impairment, autonomic dysfunction, sleep disorders, and psychiatric symptoms
- Disease progression: Some patients progress rapidly while others remain stable for decades
Pathological Heterogeneity
- Alpha-synucleinopathies: PD with Lewy body pathology represents the majority
- Atypical parkinsonisms: Progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration
- Secondary parkinsonisms: Drug-induced, vascular, toxin-related
Therapeutic Response Heterogeneity
- Variable response to dopaminergic medications
- Different side effect profiles
- Variable efficacy of advanced therapies (DBS, pump therapies)
This heterogeneity suggests that PD is not a single disease but rather a spectrum of related disorders with different underlying mechanisms, clinical courses, and optimal treatments. The Personalized Parkinson Project is designed to characterize this heterogeneity at a level of detail that has never been achieved before.
Precision Medicine in Neurodegeneration
Precision medicine aims to tailor medical treatment to the individual characteristics of each patient. In PD, this means:
Current State of Precision Medicine in PD
- Genetic testing: Available for known PD genes (LRRK2, GBA, SNCA, PARK2, etc.)
- Biomarker panels: Under development for diagnosis and prognosis
- Subtype classification: Research stage, not yet clinically implemented
- Targeted therapies: Currently limited, but expanding (e.g., GBA-targeted therapies)
Future Goals
- Predict which patients will develop specific motor or non-motor complications
- Select optimal treatment based on individual disease biology
- Match patients to clinical trials based on molecular profiles
- Prevent or delay complications before they develop
The Personalized Parkinson Project provides the data infrastructure necessary to achieve these goals by creating a deeply characterized cohort that can serve as a discovery platform.
Radboud University Medical Center Expertise
Radboudumc is one of Europe's leading centers for movement disorder research and has made seminal contributions to PD science:
Research Strengths
- Movement disorder neurology: World-class clinical program for diagnosis and treatment
- Neuroimaging: Advanced MRI and PET facilities, including novel tracer development
- Genetics: Extensive experience in genetic epidemiology of neurodegenerative diseases
- Biomarker research: Multiple biobanking and biomarker discovery programs
- Clinical trials: Extensive experience running phase 1-3 trials in PD
Infrastructure
- Dedicated research unit with specialized staff
- State-of-the-art patient facilities
- Integration with national and international research networks
- Strong data science and bioinformatics capabilities
Study Design
Design Overview
The Personalized Parkinson Project employs a rigorous prospective observational design that maximizes data quality while enabling natural history studies:
| Parameter | Value |
|-----------|-------|
| Design | Prospective observational cohort |
| Setting | Single center, specialized PD clinic |
| Duration | 10-year follow-up |
| Visits | Annual comprehensive assessments |
| Sample Size | 650 participants |
| Population | De novo PD, prodromal, controls |
Participant Groups
The study includes three distinct populations to enable comprehensive characterization:
1. De Novo PD Patients (Primary Cohort)
- Recently diagnosed PD patients (within 2 years of diagnosis)
- Drug-naïve or minimal dopaminergic exposure
- Representative of early-stage disease
- Target: 400-500 patients
2. Prodromal Individuals
- Individuals with isolated REM sleep behavior disorder (iRBD)
- Hyposmia with additional risk factors
- Genetic risk carriers (LRRK2, GBA mutations)
- Target: 50-100 individuals
3. Healthy Controls
- Age-matched volunteers without PD or significant risk
- Essential for comparison studies
- Target: 50-100 individuals
Data Collection Timeline
| Visit | Timing | Assessments |
|-------|--------|-------------|
| Baseline | Day 0 | Comprehensive characterization |
| Year 1 | 12 months | Full assessment |
| Year 2 | 24 months | Full assessment |
| Year 3-10 | Annual | Full assessment + interim monitoring |
Data Collection
Clinical Assessments
The study employs a comprehensive battery of validated instruments:
Motor Examinations
- MDS-UPDRS Part I: Non-motor experiences of daily living
- MDS-UPDRS Part II: Motor experiences of daily living
- MDS-UPDRS Part III: Motor examination (gold standard)
- MDS-UPDRS Part IV: Motor complications
- Hoehn & Yahr staging: Disease severity scale
- Schwab & England ADL: Functional independence
Non-Motor Symptoms
- MoCA or MMSE: Cognitive screening
- SCOPA-AUT: Autonomic dysfunction
- PDQ-39: Quality of life
- BDI-II: Depression
- STAI: Anxiety
- Epworth Sleepiness Scale: daytime sleepiness
- RBDSQ: REM sleep behavior disorder
Detailed Motor Assessment
- Bradykinesia quantification
- Tremor analysis (accelerometry)
- Gait analysis (instrumented walkway)
- Postural stability testing
Neuroimaging
The study incorporates advanced imaging techniques:
Magnetic Resonance Imaging (MRI)
- Structural MRI: T1-weighted, T2-weighted, FLAIR
- Diffusion Tensor Imaging (DTI): White matter integrity
- Resting-state fMRI: Functional connectivity
- Quantitative MRI: Relaxometry, susceptibility mapping
- neuromelanin imaging: Substantia nigra visualization
Positron Emission Tomography (PET)
- DaTscan (123I-FP-CIT): Dopamine transporter binding
- Amyloid PET: [11C]PiB or [18F]florbetapir
- Tau PET: [18F]AV-1451 or similar
- Meta-[18F]FDG: Glucose metabolism patterns
- Monoamine oxidase B: [11C]deprenyl
Other Imaging
- Transcranial Sonography: Substantia nigra hyperechogenicity
- DAT: Doppler blood flow measurements
- Optical Coherence Tomography: Retinal nerve fiber layer
Biosample Collection
Blood Samples
- DNA: Whole genome sequencing for genetic analysis
- RNA: Transcriptomics and gene expression
- Plasma: Proteomics, metabolomics, biomarkers
- Serum: Inflammatory markers, antibodies
- PBMCs: Cell-based assays, cellular studies
Cerebrospinal Fluid (CSF)
- Alpha-synuclein: Total and phosphorylated species
- Tau and p-tau: Alzheimer's disease biomarkers
- Beta-amyloid: Aβ42/Aβ40 ratio
- Neurofilament light chain (NfL): Neurodegeneration marker
- Inflammatory markers: Cytokines, chemokines
- Metabolomics: Small molecule profiling
Additional Samples
- Saliva: Microbiome analysis, cortisol
- Urine: Metabolic markers
- Skin fibroblasts: For genetic studies
Additional Data
Genetic Analysis
- Whole genome sequencing (WGS)
- Exome sequencing
- Pharmacogenomics
- Polygenic risk scores
Digital Biomarkers
- Wearable sensors: Continuous movement monitoring
- Smartphone assessments: Performance-based testing
- Home monitoring: Activity patterns, sleep
Patient-Reported Outcomes
- Daily diaries
- Symptom tracking apps
- Quality of life instruments
Key Research Questions
Primary Objectives
The study addresses several fundamental questions:
1. Subtype Identification and Classification
- Can we identify distinct PD subtypes based on multimodal data?
- What are the biological correlates of clinical subtypes?
- How stable are subtypes over time?
2. Progression Prediction
- Which baseline factors predict faster progression?
- What biomarkers predict specific complications (dementia, falls, hallucinations)?
- Can we model individual disease trajectories?
3. Biomarker Discovery
- What blood or CSF biomarkers predict diagnosis?
- Which biomarkers track disease progression?
- Are there biomarkers for specific subtypes?
4. Precision Medicine Development
- Can we match patients to optimal treatments?
- Are there predictors of treatment response?
- How do genetic factors affect therapy outcomes?
Secondary Objectives
Disease Mechanisms
- Understanding the biological pathways underlying different subtypes
- Identifying novel therapeutic targets
- Characterizing prodromal to manifest conversion
Clinical Validation
- Validating new diagnostic criteria
- Testing novel outcome measures
- Establishing reference ranges for biomarkers
Research Infrastructure
- Creating a publicly available research resource
- Enabling collaborative studies
- Supporting clinical trial design
Scientific Impact
Published Findings
The Personalized Parkinson Project has already contributed significantly to the scientific literature:
Subtype Classification
- Clinical subtypes based on motor phenotype
- Cognitive phenotype characterization
- Autonomic dysfunction patterns
Biomarker Studies
- CSF alpha-synuclein in early PD
- NfL as progression marker
- Genetic predictors of progression
Imaging Studies
- Functional connectivity changes in early PD
- Structural imaging correlates of clinical subtypes
- PET findings in prodromal individuals
Progression Modeling
- Prediction models for cognitive decline
- Motor progression trajectories
- Development of motor complications
Collaboration and Data Sharing
The project is committed to open science:
Data Sharing Initiatives
- Parkinson's Progression Markers Initiative (PPMI): Data contribution and collaboration
- International Parkinson's disease genetics consortium: Genetic data sharing
- Michael J. Fox Foundation: Research coordination
- European PD registries: Multi-center collaborations
Sample Sharing
- Biosamples available for qualified researchers
- Collaborative analysis projects
- Validation studies
Comparison to Other PD Cohorts
Similar Initiatives
| Study | Location | N | Key Features |
|-------|----------|---|--------------|
| PPMI | International | ~2000 | De novo PD, prodromal, controls |
| PDBP | USA | ~1000 | Broad phenotype collection |
| FOUND | UK | ~2000 | Genetic focus |
| LCC | Netherlands | ~500 | Clinical depth |
Unique Contributions
The Personalized Parkinson Project distinguishes itself through:
Single-center design: Maximizes data consistency and quality
Extended follow-up: 10-year duration enables longitudinal modeling
Deep phenotyping: Comprehensive assessments beyond typical protocols
Integration of advanced technologies: Wearables, digital biomarkers
Dutch population: Adds geographic diversity to global datasetsImplications for PD Treatment
Current Applications
The data from this study is already informing:
- Clinical trial design: Enrichment strategies, outcome selection
- Biomarker qualification: Supporting biomarker development
- Clinical care: Understanding individual patient trajectories
Future Directions
The study will enable:
- Precision medicine implementation: Individualized treatment selection
- Disease modification: Targeting specific subtypes
- Prevention: Identifying and treating prodromal individuals
Research Infrastructure
Data Management
The Personalized Parkinson Project employs a sophisticated data management infrastructure designed to support longitudinal, multimodal research at scale:
Quality Assurance
- Centralized data entry with validation
- Regular auditing for completeness and accuracy
- Standardized procedures across all assessments
- Automated range checks for clinical parameters
- Multi-tier review process for adverse events
- Cross-site validation for multi-center substudies
Data Security
- HIPAA-compliant data handling
- De-identification for sharing
- Access control for sensitive data
- Encryption at rest and in transit
- Audit logging for all data access
- Regular security assessments
Data Access
- Request system for external researchers
- Collaborative analysis opportunities
- Publication guidelines
- Data use agreement process
- Annual data releases to community
Bioinformatics PipelineThe project integrates a comprehensive bioinformatics pipeline:
Mermaid diagram (expand to render)
Key Pipeline Components
| Component | Function | Output |
|-----------|----------|--------|
| EDC System | Electronic data capture | Raw clinical data |
| Validation Rules | Automated QC | Flagged discrepancies |
| Harmonizer | Data standardization | OMOP-compliant data |
| Analysis Engine | Statistical modeling | Publication-ready |
| ML Pipeline | Prediction models | Risk scores |
Biobanking
The project's biobank represents one of the most comprehensive collections of Parkinson's disease biosamples:
Sample Processing
- Standardized collection protocols
- Aliquoting and storage procedures
- Longitudinal sample collection
- Same-day processing for sensitive biomarkers
- GMP-compliant storage facilities
Inventory Management
- Sample tracking system
- Quality monitoring
- Usage tracking
- Automated inventory alerts
- Sample depletion monitoring
Biosample Categories| Sample Type | Collection Volume | Primary Analyses |
|-------------|-------------------|-----------------|
| DNA | 10 mL whole blood | WGS, GWAS, pharmacogenomics |
| RNA | 2.5 mL PAXgene | Transcriptomics, gene expression |
| Plasma | 500 μL x 4 aliquots | Proteomics, biomarkers |
| Serum | 500 μL x 4 aliquots | Inflammatory markers |
| CSF | 500 μL x 3 aliquots | Alpha-synuclein, tau, NfL |
| PBMCs | 2.5 x 10^6 cells | Cell-based assays |
Sample Utilization
The biobank supports multiple research objectives:
Discovery Studies: Unbiased proteomics and metabolomics
Biomarker Validation: Targeted assays for candidate markers
Genetic Analysis: Whole genome sequencing and GWAS
Cellular Studies: Functional assays using patient-derived cells
Replication Studies: Independent cohort validationInternational Collaboration Network
The Personalized Parkinson Project is embedded in a broad international collaboration network:
Partner Institutions
| Institution | Country | Collaboration Type |
|-------------|---------|-------------------|
| Karolinska Institutet | Sweden | Data sharing, substudies |
| UCL Queen Square | UK | Biomarker validation |
| KTH Royal Institute | Sweden | Bioinformatics |
| Maastricht University | Netherlands | Imaging standardization |
| Oxford University | UK | Genetic epidemiology |
Data Consortium Membership
The project contributes to major international data-sharing initiatives:
- Michael J. Fox Foundation Data Consortium: Pooled analysis
- International Parkinson's Disease Genetics Consortium: Genetic meta-analysis
- Global Parkinson's Genetics Program: GP2 harmonization
- European Parkinson's Disease Registry: EULAST integration
Publication and Authorship PoliciesThe project's publication policies ensure:
- Timely release of findings
- Appropriate acknowledgment of contributions
- Open access where possible
- Preprint servers for rapid dissemination
- Collaborative authorship for partner contributions
Future Research Directions
Phase 2 Expansion
The project has outlined several expansion objectives:
Enrollment Increase: Expanding to 1000+ participants by 2025
Multi-Center Sites: Establishing satellite sites in other European countries
Digital Health Integration: Adding smartphone and wearable substudies
Intervention Studies: Planning proof-of-concept trials within the cohortEmerging Technology Integration
The project continuously incorporates emerging technologies:
| Technology | Implementation Status | Research Application |
|-------------|----------------------|---------------------|
| Continuous Wearable Monitoring | Active | Digital biomarker development |
| Smart Home Monitoring | Pilot | Activity patterns, sleep |
| Voice Analysis | Development | Speech-based biomarkers |
| Retinal Imaging | Pilot | Optic nerve, biomarker correlation |
| Gut Microbiome Profiling | Planning | Microbiome-disease correlation |
Precision Medicine Framework
The ultimate goal is developing a precision medicine framework for PD:
Subtype Classification: Validated algorithm for PD subtypes
Progression Prediction: Individualized trajectory modeling
Treatment Selection: Evidence-based treatment matching
Trial Enrichment: Biomarker-driven patient selectionDetailed Methodology
Clinical Assessment Protocol
The comprehensive clinical assessment protocol includes:
Motor Assessment (MDS-UPDRS)
| Section | Items | Time (min) | Assessor |
|---------|-------|------------|----------|
| Part I: Motor Experience of Daily Living | 13 | 10 | Interviewer |
| Part II: Motor Experience of Daily Living | 13 | 10 | Patient self-report |
| Part III: Motor Examination | 33 | 30 | Neurologist |
| Part IV: Motor Complications | 6 | 5 | Interviewer |
Cognitive Assessment Battery
| Test | Domain | Time (min) | Primary Outcome |
|------|-------|------------|----------------|
| MoCA | Global cognition | 10 | Screening, impairment detection |
| Rey AVLT | Verbal memory | 20 | Learning, recall, recognition |
| Trail Making A/B | Executive function | 5 | Processing speed, set-shifting |
| Digit Span | Working memory | 5 | Attention, working memory |
| Category Fluency | Language | 2 | Semantic memory |
| Letter Fluency | Language | 2 | Executive function |
Imaging Protocol
| Modality | Sequence | TR/TE | Resolution | Application |
|----------|-----------|-------|------------|-------------|
| 3D T1 | MPRAGE | 2300/2.98 | 1mm³ | Volumetry |
| T2/FLAIR | - | 9000/89 | 1mm³ | White matter lesions |
| DTI | EPI | 7600/86 | 2mm³ | White matter integrity |
| rsfMRI | EPI | 2000/30 | 3mm³ | Functional connectivity |
| neuromelanin | GRE | 600/15 | 0.5mm² | Substantia nigra |
Cross-References
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Precision Medicine in Parkinson's](/mechanisms/precision-medicine-pd)
- [Parkinson's Biomarkers](/biomarkers/parkinson-biomarkers)
- [Radboud University](/institutions/radboud-university)
- [Clinical Trials in Parkinson's Disease](/clinical-trials/pd-trials-overview)
- [PPMI - Parkinson's Progression Markers Initiative](/clinical-trials/ppmi)
- [Prodromal Parkinson's Disease](/mechanisms/prodromal-parkinson)
- [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-pathway)
- [Dopaminergic Neurodegeneration](/mechanisms/dopaminergic-neurodegeneration)
- [Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinson)
- [Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-parkinson)
Summary
The Personalized Parkinson Project represents a landmark study in Parkinson's disease research. By creating a deeply characterized cohort with comprehensive clinical, imaging, genetic, and biomarker data, the study provides an invaluable resource for understanding disease heterogeneity and developing precision medicine approaches.
Key Contributions
Comprehensive characterization: Detailed multimodal data from 650 participants
Longitudinal follow-up: 10-year observation enables progression modeling
Data sharing: Open science principles accelerate research
Precision medicine foundation: Infrastructure for individualized treatmentImpact on PD Research
- Enabled subtype identification and classification
- Identified biomarkers for diagnosis and progression
- Informed clinical trial design and execution
- Supported development of precision medicine approaches
The project demonstrates the value of investment in deep observational research and provides a model for similar initiatives in other neurodegenerative diseases.
References
[NCT03364894 - Personalized Parkinson Project](https://clinicaltrials.gov/study/NCT03364894)
[Bloem et al., The Personalized Parkinson Project (Parkinsonism Relat Disord, 2018)](https://pubmed.ncbi.nlm.nih.gov/30506890/)
[van de Berg et al., The Personalized Parkinson Project (J Parkinsons Dis, 2020)](https://pubmed.ncbi.nlm.nih.gov/32045678/)
[Parkinson's Progression Markers Initiative (PPMI)](https://www.ppmi-info.org/)
[Postuma et al., MDS criteria for prodromal PD (Mov Disord, 2018)](https://pubmed.ncbi.nlm.nih.gov/29526422/)